Search results
Results from the WOW.Com Content Network
Insomnia is one of the most common sleep disorders, with the Centers for Disease Control and Prevention reporting that as many as one in two adults experience short-term bouts, while one in 10 may ...
Over time, insomnia can also contribute to chronic health issues like heart disease, high blood pressure, obesity, chronic pain syndrome and diabetes. What are the causes or risk factors for insomnia?
Pantoprazole, sold under the brand name Protonix, among others, is a medication used for the treatment of stomach ulcers, short-term treatment of erosive esophagitis due to gastroesophageal reflux disease (GERD), maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including Zollinger–Ellison syndrome.
Around 2-6% of adults with insomnia use somnifacients to aid sleep. [2] However, somnifacients only benefit transient or short-term insomnia but not chronic insomnia. [ 3 ] It is because somnifacients lack supportive evidence for sleep aids in chronic insomnia, and chronic use of somnifacients leads to many adverse effects .
A new study reveals a shocking potential cause for insomnia.
Aponal, Quitaxon, Sinequan – a tricyclic antidepressant used to treat nerve pain, insomnia; similar to imipramine; Anquil – an antipsychotic primarily used to control antisocial hypersexual behaviour; Aricept – used to slow the progression of Alzheimer's disease
Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia. According to a survey by Japan’s Ministry of Health, Labour and Welfare in 2018, about 20% of Japanese adults struggle to get enough rest from sleep.
Daridorexant is indicated for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. [1] The medication has been found to significantly improve latency to persistent sleep (LPS), wake after sleep onset (WASO), and subjective total sleep time (TST) in regulatory clinical trials. [1]